Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5050
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors.

    To find out more about Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Protein Kinase Inhibitors
The protein kinase drug report part comprises defined and up to date development strategies for 648 drugs in oncology within the portfolio of 212 companies world-wide, from Ceased to Marketed. The report extensively analyses their 183 identified drug targets, organized into 278 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Protein Kinase Inhibitors
5.1 The Scope of this Report 38
6 Consider the Therapeutic Target Among Protein Kinase Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (183 Drug Targets) 42-516
7 Emerging New Products to Established Ones: Drug Target Strategies of Protein Kinase Drugs in Oncology by their Highest Stage of Development (278 Drug Target Strategies and 648 Drugs) 517-945
8 Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Cancer Drugs by Compound Strategy (8 Compound Strategies) 946-1013
9 Selecting Indication for Protein Kinase Drugs in Oncology (70 Cancer Indications) 1014-1223
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Protein Kinase Drug Pipeline in Oncology by Investigator (212 Investigators and 648 Drugs) 1224-2939
11 Disclaimer 2940
Figures: Includes 8 Figures
Tables: Includes 389 Tables
Total Number of Pages: 2,940

This Report Includes the Following Companies:
4SC
AB Science
Abbott
Abiogen
AC Immune
Acceleron Pharma
ACT Biotech
Active Biotech
Adaptimmune
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agenus
Aida Pharmaceuticals
Alethia Biotherapeutics
Allist Pharmaceuticals
Allostera
AlphaVax
Ambit Biosciences
Amgen
Amphora
Ansaris
Antisense Pharma
Anza Therapeutics
Apogee Biotechnology
Apotex
Ardea Biosciences
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
AVEO
AVI BioPharma
Avila Therapeutics
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Benitec
Berkeley Lab
Betapharma
Bio-Path Holdings
BioAxone
Biogen Idec
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
Biotecnol
Biotica Technology
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Callisto Pharmaceuticals
Cambrex
CanBas
Cancer Advances
Cancer Research Technology
Catalyst Biosciences
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Celleron
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CerRx
CG Therapeutics
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Clinical Data
CompleGen
Compugen
CoNCERT Pharmaceuticals
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CritiTech
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokine PharmaSciences
Cytokinetics
Cytopia
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dyax
EGEN Inc
Eisai
Elara Pharmaceuticals
Eli Lilly
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
FibroGen
Galapagos
Galectin Therapeutics
Galena Biopharma
Generex
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
GPC Biotech
Gradalis
Hanmi
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hutchison China MediTech
Hypha Discovery
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Incozen Therapeutics
Incyte Corporation
Inhibiton Therapeutics
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intellikine
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Jina Pharmaceuticals
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Karus Therapeutics
Keryx Biopharmaceuticals
Kiadis
Kinex
Kirin Pharma
KuDOS
Kyowa Hakko Kirin
Leo
Lexicon Pharmaceuticals
Ligand
Lipotek
Mannkind
Marina Biotech
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Molecular LogiX
MolMed
Mologen
Momotaro-Gene
Myrexis
Nano Terra
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
NexusPharma
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
Oncalis
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pathway Therapeutics
Patrys
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Phoenix Biotechnology
PHusis Therapeutics
Pieris
Pierre Fabre
Piramal
PIramed
Portola Pharmaceuticals
Proacta
Progenics Pharmaceuticals
ProMetic Life Sciences
Protgen
Protherics
Provid
QLT
Quantum Pharmaceuticals
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samtheo Biopharma
Samyang
Sanofi
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
Schering-Plough
Selvita
Semafore Pharmaceuticals
Sentinel Oncology
SGX Pharmaceuticals
Shionogi
Shire
Silence Therapeutics
Sunesis
SuperGen
Supratek Pharma
Swedish Orphan Biovitrum
Switch Pharma
Symphogen
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
TargeGen
Tau Therapeutics
TauTaTis
TCD Pharma
Tekmira Pharmaceuticals
Telik
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tragara Pharmaceuticals
Transgene
TransTech Pharma
Trion Pharma
UCB
UMN Pharma
United Biomedical
Vaccinex
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Virionics
ViroMed
Wyeth
Xcovery
Xencor
Xerion
Yakult Honsha
YM BioSciences
Zensun
Zenyaku Kogyo
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
abagovomab
AC-480
ADXS11-001
AE-37
AEG-35156
AF-802
afatinib
aflibercept
AGS-003
AGS-1C4D4
alvocidib
AMG-386
Angiozyme
ANZ-207
apatinib
apricoxib
AR-42
ARC-100
ARQ-197
astuprotimut-r
AT-7519
AT-9283
Auto TAG vaccine
AVX-701
axitinib
AZD-8055
AZD-8931
bafetinib
barasertib
bardoxolone methyl
belagenpumatucel-L
bevacizumab
BEZ-235
BGT-226
BI-811283
BIBF-1120
BMS-690514
BMS-754807
BMS-777607
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
BV-NSCLC-001
Cabozantinib
CAL-101
capecitabine
catumaxomab
CB-10-01
CBP-501
CC-223
CDX-1307
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
CreaVax-PC
crizotinib
CRLX-101
CV-9103
CV-9201
CVac
dacomitinib
dalotuzumab
danusertib
dasatinib
DCVax-prostate
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-75
E-7820
emepepimut-S
endoxifen
eniluracil
ENMD-2076
enzastaurin hydrochloride
erlotinib
everolimus
foretinib
fostamatinib disodium
ganitumab
gefitinib
GI-4000
GSK-1120212
GSK-2118436
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
HS-110
IC-83
icotinib hydrochloride
icrucumab
ICT-107
idronoxil
imatinib mesilate
imMucin
IMO-2055
IMP-321
INCB-028060
INSM-18
interleukin-12
ipilimumab
irinotecan
irinotecan hydrochloride
ISA-P53-01
JI-101
JX-594
KD032
KX2-391
L19-IL2
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
linsitinib
LipoVIL12
LY-2090314
masitinib
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
MK-1775
MKC-1
MLN-8237
MM-111
mocetinostat
motesanib diphosphate
motexafin gadolinium
MVA-BN Her-2 vaccine
nadroparin
neratinib
nilotinib
nimotuzumab
NPB-001-056
oblimersen sodium
olaparib
ON-01910
onartuzumab
OncoVAX
Onyvax-105
OSI-027
OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
P276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
PD-0332991
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
PHA-848125AC
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
PROSTVAC
PSMA ADC
PX-12
PX-866
quinacrine
quizartinib dihydrochloride
RAF-265
ramucirumab
regorafenib
Reximmune-C
Rexin-G
ridaforolimus
rilotumumab
rindopepimut
rintatolimod
romidepsin
ruxolitinib
RX-0201
RX-0201-N
S-488410
SCH-900776
SCIB-1
seliciclib
selumetinib
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
Survivac
talmapimod
talminogene laherparepvec
tandutinib
tegafur + uracil
telatinib
temsirolimus
terameprocol
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tivozanib
tocilizumab
trabedersen
trastuzumab
triciribine phosphate
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
velimogene aliplasmid
vemurafenib
verpasep caltespen
vismodegib
vitespen
volasertib
volociximab
vosaroxin
VX-001
WX-671
XL-147
XL-281
XL-413
XL-647
XL-765
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors.
    To find out more about Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Protein Kinase Inhibitors is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More


Triple Analysis: Colorectal Cancer, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lymphoma and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More


Cancer Peptides: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More